ClinicalTrials.gg
Not yet recruitingNCT06746467Updated Dec 24, 2024

Corneal Topography in Vernal Keratoconjunctivitis

An observational study in Keratoconjunctivitis, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
44
Sex
All
01

Study summary

To evaluate the corneal topographic changes in VKC patients using Pentacam and prevalence of KC development in VKC.

Read the detailed description

Vernal keratoconjunctivitis (VKC) is a chronic allergic disease, with seasonal periods of exacerbation.VKC is characterized by itching, photophobia. white mucous discharge, lacrimation, foreign body sensation, and pain due to corneal involvement of shield ulcers. Corneal involvement in VKC involves injury to the superficial and basal epithelial layers and anterior stroma . Excessive eye rubbing and a slow release of matrix metalloproteinases penetrate the cornea in presence of chronic epithelial damage causing astigmatism and corneal ectasia . These changes may be undetected until advanced complications such as keratoconus(KC) with thinning and protrusion of cornea leading to myopia and astigmatism . These changes can be measured accurately by corneal topography, making it the gold standard in the screening of keratoconus and other corneal ectasias . Corneal topography is a method of computer-assisted examination of the cornea in which multiple concentric light rings are projected on cornea. Changes in corneal topography indices to be studied include changes in effective refeactivepower ,asphericity , corneal asymmetry index and visual performance . It is a non-invasive exploratory technique to analyse both qualitatively and quantitatively the morphology of the cornea . The Penta Cam is a cornea and anterior segment topography device, based on a rotating Scheimpflug camera. Its optical cross-sectional analysis that helps in imaging of anterior and posterior corneal surfaces which provides with fullpachymetric map and many other data such as corneal aberrometry and densitometry that allow early detection of ectasia.

02

Conditions studied

  • Keratoconjunctivitis

Browse trials for

Keywords

  • corneal topography on vkc
03

In context

Keratoconjunctivitis

27 studies on the registry are indexed under Keratoconjunctivitis; 3 are open to participants now.

Browse Keratoconjunctivitis studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients will be selected from primary clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

clinical diagnosis of vernal keratoconjunctivitis -

Exclusion criteria

Exclusion Criteria:

patients with corneal disease as corneal opacity, corneal dystrophy or degenerative changes patients with previous corneal surgery patients with ocular trauma.

-

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
44 participants (estimated)
Patient registry
No

Interventions

  • Devicepentacam

    evaluate corneal changes by pentacam

06

What researchers measure

Primary outcomes

  1. evaluate the corneal topographic changes in VKC patients using Pentacam

    Time frame: 1 year

Secondary outcomes

  1. prevalence of KC development in VKC

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Dantas PE, Alves MR, Nishiwaki-Dantas MC. Topographic corneal changes in patients with vernal keratoconjunctivitis. Arq Bras Oftalmol. 2005 Sep-Oct;68(5):593-8. doi: 10.1590/s0004-27492005000500004. Epub 2005 Nov 28. PubMed 16322853 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 24, 2024
StartEst.
Jun 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06746467
Lead sponsor
Assiut University
Responsible party
Monica Basem Fayez (assistant lecture, Assiut University) — Principal investigator
First posted
Dec 24, 2024
Start date
Jun 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 24, 2024

Study contacts

monica basem fayez, doctor
Contact
Monicabasem668@gmail.com
+201202961139
dalia mohamed mohamed, professer
Contact
+201223212962

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion